```html

Zollinger‑Ellison Syndrome (Gastrinoma) – Benign: A Comprehensive Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to release large volumes of gastric acid. The resulting hyperacidity can cause severe peptic ulcers, diarrhea, and malabsorption.

When the tumors are benign, they have not invaded surrounding tissues or metastasized to distant organs. Benign gastrinomas still cause the classic symptoms of ZES, but their long‑term outlook is generally more favorable than that of malignant (cancerous) forms.

Prevalence: ZES is estimated to occur in 1–3 per million people per year worldwide (NIH, 2020). Benign gastrinomas comprise roughly 60 % of all gastrinomas, with the remainder being malignant.

Symptoms

Symptoms stem from excess gastric acid and, to a lesser extent, the tumor’s mass effect. They can vary widely, but the most common presentations are:

Gastro‑intestinal symptoms

• Recurrent or resistant peptic ulcers – often multiple, located beyond the duodenum (e.g., in the jejunum).
• Abdominal pain – burning or cramping pain that may improve with food (due to ulcer healing) or worsen with acid exposure.
• Diarrhea – watery, sometimes greasy stools caused by acid inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools) – malabsorption of fat leading to foul‑smelling stools.
• Heartburn / gastro‑esophageal reflux disease (GERD) – due to high acid volume.

Systemic symptoms

• Weight loss – from malabsorption and chronic diarrhea.
• Fatigue – secondary to anemia or nutrient deficiencies.
• Muscle cramps – electrolyte disturbances (low potassium, magnesium).

Symptoms related to the tumor itself

• Abdominal mass – palpable or felt on imaging if the tumor grows large.
• Low‑grade pain – when the tumor presses on adjacent structures.

Because the acid output can be up to ten times normal, patients may develop ulcers that are recurrent despite standard therapy, which is a key clinical clue.

Causes and Risk Factors

Primary cause

Benign ZES results from sporadic (non‑inherited) gastrin‑producing neuroendocrine tumors (NETs) arising in the:

• Duodenum (≈ 70 % of cases)
• Pancreas (≈ 20 % of cases)
• Rarely, ectopic locations (e.g., lymph nodes, jejunum)

Genetic risk factor

Although most cases are sporadic, MEN‑1 syndrome dramatically increases risk. MEN‑1 is an autosomal‑dominant disorder caused by mutations in the MEN1 tumor‑suppressor gene. Individuals with MEN‑1 have a 20‑30 % lifetime risk of developing a gastrinoma.

Other risk factors

• Family history of NETs or MEN‑1.
• Age – incidence rises after the third decade.
• There are no confirmed lifestyle or environmental risk factors.

Diagnosis

Diagnosing benign ZES requires confirming hypergastrinemia, demonstrating acid hypersecretion, and locating the gastrinoma. A systematic approach is recommended.

1. Laboratory tests

• Fasting serum gastrin level – values > 1000 pg/mL are highly suggestive; levels 2–5 times the upper limit of normal (ULN) with a gastric pH < 2 are diagnostic (Cleveland Clinic).
• Secretin stimulation test – after an intravenous bolus of secretin, gastrin levels rise > 120 pg/mL in ZES, whereas they fall or stay unchanged in other causes of hypergastrinemia.
• pH monitoring – gastric pH < 2 confirms acid hypersecretion.
• Additional labs to assess nutrition: CBC, serum electrolytes, vitamins (A, D, E, K), and iron studies.

2. Imaging studies to locate the tumor

• Endoscopic ultrasound (EUS) – high sensitivity (> 80 %) for small duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – maps larger lesions and evaluates for regional lymph node involvement.
• Somatostatin receptor scintigraphy (Octreoscan®) or ^68Ga‑DOTATATE PET/CT – gold standard for detecting neuroendocrine tumors, especially when CT/MRI are equivocal.
• Selective arterial secretin stimulation test (SASS) – occasionally used when non‑invasive imaging fails.

3. Endoscopic evaluation

Upper endoscopy (EGD) is performed to visualize ulcers, obtain biopsies (to rule out H. pylori or malignancy), and sometimes to place a dual‑pH probe for ambulatory acid testing.

Diagnostic criteria summary

Criterion	Positive result
Fasting gastrin	> 1000 pg/mL or > 2×ULN with low pH
Secretin stimulation	Increase > 120 pg/mL
Acid output	Basal acid output > 15 mEq/h or gastric pH < 2
Imaging	Lesion identified in duodenum or pancreas

Treatment Options

Management targets two goals: control of gastric acid hypersecretion and removal or control of the gastrinoma. A multidisciplinary team (gastroenterologist, endocrine surgeon, nutritionist, and endocrinologist) is ideal.

1. Acid‑suppression therapy

• High‑dose proton pump inhibitors (PPIs) – omeprazole, esomeprazole, or pantoprazole 60–120 mg daily (or divided doses). PPIs are the mainstay; most patients achieve ulcer healing within weeks.
• H2‑receptor antagonists – added in refractory cases, but typically less effective than PPIs.
• Long‑term PPI use should be monitored for:
  • Vitamin B12 deficiency
  • Hypomagnesemia
  • Potential increased risk of bone fractures

2. Surgical management

Because benign gastrinomas are usually small and well‑encapsulated, curative surgery is possible in 70‑80 % of cases.

• Enucleation – removal of the tumor alone; preferred for solitary duodenal lesions.
• Pancreaticoduodenectomy (Whipple procedure) – reserved for larger pancreatic tumors or those near the ampulla.
• Laparoscopic/robotic approaches – increasingly used and associated with shorter recovery.
• Post‑operative monitoring of gastrin levels is essential to confirm cure.

3. Medical therapy for unresectable or metastatic disease

• Somatostatin analogs (Octreotide, Lanreotide) – inhibit gastrin release and can shrink tumor size.
• Targeted therapy (everolimus, sunitinib) – approved for progressive neuroendocrine tumors; data for benign gastrinomas are limited but useful in selected cases.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive tumors.

4. Lifestyle and supportive measures

• Eat smaller, frequent meals to reduce gastric acid spikes.
• Avoid trigger foods (spicy, acidic, caffeine, alcohol).
• Stay hydrated; replace electrolytes lost in diarrhea.
• Supplement vitamin B12, calcium, and vitamin D if labs are low.

Living with Zollinger‑Ellison Syndrome (gastrinoma) – Benign

Even after successful treatment, many patients need lifelong acid suppression and periodic monitoring.

Daily management tips

1. Take PPIs exactly as prescribed – usually before breakfast and dinner.
2. Schedule regular follow‑up labs – fasting gastrin, magnesium, calcium, vitamin B12 every 6–12 months.
3. Monitor stool pattern – persistent watery stools warrant evaluation for malabsorption.
4. Maintain a symptom diary – record ulcer pain, heartburn, and diarrhea; share with your doctor.
5. Vaccinations – patients on high‑dose PPIs may have reduced absorption of certain vaccines; discuss with your clinician.
6. Exercise – moderate activity improves gastrointestinal motility and overall health.

Psychosocial considerations

Living with a chronic endocrine condition can cause anxiety. Support groups (e.g., Neuroendocrine Tumor Patient Foundation) and counseling can be beneficial.

Prevention

Because most benign gastrinomas arise sporadically, primary prevention is limited. However, the following measures may reduce risk or aid early detection:

• Genetic counseling for families with MEN‑1; early screening with fasting gastrin and imaging can catch tumors before complications.
• Avoid chronic H. pylori infection – while not a cause of gastrinomas, eradication reduces background ulcer disease.
• Maintain a balanced diet and healthy weight to avoid additional gastrointestinal stress.

Complications

If untreated or poorly controlled, excessive acid can lead to serious health problems:

• Refractory or perforated peptic ulcers – may require emergent surgery.
• Gastrointestinal bleeding – chronic ulceration can cause anemia.
• Malabsorption syndrome – loss of fat‑soluble vitamins (A, D, E, K) causing osteopenia, coagulopathy, or night blindness.
• Electrolyte disturbances – chronic diarrhea leads to hypokalemia, hypomagnesemia, metabolic alkalosis.
• Gastro‑esophageal reflux disease (GERD) – can progress to Barrett’s esophagus.
• Rare progression to malignant gastrinoma – especially in MEN‑1 patients; regular imaging is essential.

When to Seek Emergency Care

---

Sources: Mayo Clinic, Cleveland Clinic, National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), peer‑reviewed journals (e.g., Journal of Clinical Endocrinology & Metabolism, 2022). All information is for educational purposes and does not replace professional medical advice.

```